These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
393 related articles for article (PubMed ID: 11784625)
1. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Zoccali C; Bode-Böger S; Mallamaci F; Benedetto F; Tripepi G; Malatino L; Cataliotti A; Bellanuova I; Fermo I; Frölich J; Böger R Lancet; 2001 Dec 22-29; 358(9299):2113-7. PubMed ID: 11784625 [TBL] [Abstract][Full Text] [Related]
2. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology? Busch M; Fleck C; Wolf G; Stein G Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555 [TBL] [Abstract][Full Text] [Related]
3. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. Ravani P; Tripepi G; Malberti F; Testa S; Mallamaci F; Zoccali C J Am Soc Nephrol; 2005 Aug; 16(8):2449-55. PubMed ID: 15944335 [TBL] [Abstract][Full Text] [Related]
4. Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study. Aucella F; Maas R; Vigilante M; Tripepi G; Schwedhelm E; Margaglione M; Gesualdo L; Boeger R; Zoccali C Atherosclerosis; 2009 Dec; 207(2):541-5. PubMed ID: 19501358 [TBL] [Abstract][Full Text] [Related]
5. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients. Kumagai H; Sakurai M; Takita T; Maruyama Y; Uno S; Ikegaya N; Kato A; Hishida A Am J Kidney Dis; 2006 Nov; 48(5):797-805. PubMed ID: 17059999 [TBL] [Abstract][Full Text] [Related]
6. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. Mallamaci F; Tripepi G; Maas R; Malatino L; Böger R; Zoccali C J Am Soc Nephrol; 2004 Feb; 15(2):435-41. PubMed ID: 14747391 [TBL] [Abstract][Full Text] [Related]
7. The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease. Testa A; Spoto B; Tripepi G; Mallamaci F; Malatino L; Fatuzzo P; Maas R; Boeger R; Zoccali C J Hypertens; 2005 Oct; 23(10):1825-30. PubMed ID: 16148605 [TBL] [Abstract][Full Text] [Related]
8. Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease. Osanai T; Nakamura M; Sasaki S; Tomita H; Saitoh M; Osawa H; Yamabe H; Murakami S; Magota K; Okumura K Kidney Int; 2003 Dec; 64(6):2291-7. PubMed ID: 14633154 [TBL] [Abstract][Full Text] [Related]
9. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Tripepi G; Mattace Raso F; Sijbrands E; Seck MS; Maas R; Boger R; Witteman J; Rapisarda F; Malatino L; Mallamaci F; Zoccali C Clin J Am Soc Nephrol; 2011 Jul; 6(7):1714-21. PubMed ID: 21642364 [TBL] [Abstract][Full Text] [Related]
10. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Tarnow L; Hovind P; Teerlink T; Stehouwer CD; Parving HH Diabetes Care; 2004 Mar; 27(3):765-9. PubMed ID: 14988299 [TBL] [Abstract][Full Text] [Related]
11. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Nanayakkara PW; Teerlink T; Stehouwer CD; Allajar D; Spijkerman A; Schalkwijk C; ter Wee PM; van Guldener C Kidney Int; 2005 Nov; 68(5):2230-6. PubMed ID: 16221223 [TBL] [Abstract][Full Text] [Related]
12. Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients. Kanbay M; Afsar B; Siriopol D; Unal HU; Karaman M; Saglam M; Eyileten T; Gezer M; Verim S; Oguz Y; Vural A; Ortiz A; Johnson RJ; Covic A; Yilmaz MI Int Urol Nephrol; 2016 Jul; 48(7):1129-36. PubMed ID: 27007614 [TBL] [Abstract][Full Text] [Related]
13. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Nijveldt RJ; Teerlink T; Van Der Hoven B; Siroen MP; Kuik DJ; Rauwerda JA; van Leeuwen PA Clin Nutr; 2003 Feb; 22(1):23-30. PubMed ID: 12553946 [TBL] [Abstract][Full Text] [Related]
14. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Kielstein JT; Zoccali C Am J Kidney Dis; 2005 Aug; 46(2):186-202. PubMed ID: 16112037 [TBL] [Abstract][Full Text] [Related]
15. Asymmetric dimethylarginine and all-cause mortality: a systematic review and meta-analysis. Zhou S; Zhu Q; Li X; Chen C; Liu J; Ye Y; Ruan Y; Hei Z Sci Rep; 2017 Mar; 7():44692. PubMed ID: 28294182 [TBL] [Abstract][Full Text] [Related]
16. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Böger RH; Sullivan LM; Schwedhelm E; Wang TJ; Maas R; Benjamin EJ; Schulze F; Xanthakis V; Benndorf RA; Vasan RS Circulation; 2009 Mar; 119(12):1592-600. PubMed ID: 19289633 [TBL] [Abstract][Full Text] [Related]